Quarterly ResultMay 5, 2026, 07:18 AM
Q32 Bio Q1 Net Loss $(7.6)M; Cash $50.8M; Raises Capital
AI Summary
Q32 Bio Inc. reported a net loss of $(7.6) million for the first quarter ended March 31, 2026, an improvement from $(11.0) million in the prior year period. The company's cash and cash equivalents increased to $50.8 million, supported by a $10.4 million Registered Direct Offering completed in February 2026. Operating expenses significantly decreased, with research and development costs nearly halved. Additionally, Q32 Bio established an At-The-Market (ATM) offering program, raising $13.8 million post-quarter-end and authorizing an additional $75 million.
Key Highlights
- Net loss for Q1 2026 was $(7.6) million, an improvement from $(11.0) million in Q1 2025.
- Cash and cash equivalents increased to $50.8 million as of March 31, 2026, from $48.3 million at year-end 2025.
- Total operating expenses decreased to $7.7 million in Q1 2026 from $12.2 million in Q1 2025.
- Research and development expenses decreased to $3.2 million in Q1 2026 from $7.1 million in Q1 2025.
- Received $10.4 million net proceeds from a Registered Direct Offering completed on February 19, 2026.
- Entered an ATM offering program on March 27, 2026, with up to $14.2 million available.
- Subsequent to Q1, sold 2,326,952 shares for $13.8 million net proceeds via ATM.
- Authorized an additional $75 million for ATM sales on April 24, 2026.
Price Impact
More from QTTB